Holen Sie sich die Stockscreener-App
1.45
5.84%
0.08
Vorhandelsmarkt:
1.43
-0.02
-1.38%
Gri Bio Inc Aktie (GRI) Neueste Nachrichten
Q2 Earnings Estimate for GRI Bio Issued By HC Wainwright - Defense World
Kalkine : GRI Bio Advancing in the Nasdaq Composite Healthcare Space - Kalkine Media
GRI Bio (NASDAQ:GRI) Receives “Buy” Rating from HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for GRI Bio (NASDAQ:GRI) - Defense World
GRI Bio’s (GRI) Buy Rating Reiterated at HC Wainwright - Defense World
GRI Bio (NASDAQ:GRI) Given “Buy” Rating at HC Wainwright - Defense World
GRI Bio (NASDAQ:GRI) Earns Buy Rating from HC Wainwright - Defense World
GRI Bio’s (GRI) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
# H.C. Wainwright REITERATES Buy rating on GRI Bio stock By Investing.com - Investing.com India
# H.C. Wainwright REITERATES Buy rating on GRI Bio stock - Investing.com
GRI Stock Maintains Buy Rating and $10 Price Target | GRI Stock News - GuruFocus
GRI Bio (NASDAQ:GRI) Price Target Cut to $34.00 by Analysts at Ascendiant Capital Markets - Defense World
GRI Bio: Ascendiant Capital Lowers Price Target to $34 | GRI Sto - GuruFocus
GRI Bio: Ascendiant Capital Lowers Price Target to $34 | GRI Stock News - GuruFocus
GRI Bio (NASDAQ:GRI) Trading Down 4% – Here’s Why - Defense World
GRI Bio expands at-the-market offering capacity By Investing.com - Investing.com Nigeria
GRI Bio Expands Share Offering Agreement - TipRanks
GRI Bio expands at-the-market offering capacity - Investing.com
GRI Bio (GRI) Shows Promising Preclinical Results in Pulmonary Fibrosis Treatment | GRI Stock News - GuruFocus
GRI Bio Reports Positive Preclinical Data For GRI-0621 - Nasdaq
GRI Bio (GRI) Shows Promising Preclinical Results in Pulmonary F - GuruFocus
GRI Bio IncPhase 2A Study Results For GRI-0621 Expected In Q2 2025 - marketscreener.com
GRI Bio reports progress in pulmonary fibrosis treatment By Investing.com - Investing.com India
GRI Bio reports progress in pulmonary fibrosis treatment - Investing.com
GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results - The Manila Times
GRI Bio Presents Positive Pre-Clinical Data Demonstrating - GlobeNewswire
GRI Bio Advances in IPF Treatment with Promising Trial Results - TipRanks
GRI Bio to Participate in the Virtual Investor Closing Bell Series - GlobeNewswire
GRI Bio CEO Reveals Next Steps in NKT Cell Therapy Development at Virtual Investor Series - Stock Titan
GRI Bio meets interim clinical trial enrollment goal for IPF therapy - Pulmonary Fibrosis News
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase - The Manila Times
GRI Bio CEO Reveals Latest Developments in Revolutionary NKT Cell Technology at Major Healthcare Conference - Stock Titan
GRI Bio reports positive early trial data for IPF treatment By Investing.com - Investing.com India
GRI: Q1 Financial Report Highlights and Future Prospects | GRI S - GuruFocus
GRI Bio reports positive early trial data for IPF treatment - Investing.com
GRI: Q1 Financial Report Highlights and Future Prospects | GRI Stock News - GuruFocus
GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025 - The Manila Times
GRI Bio, Inc. Reports Positive Phase 2a Interim Safety and Biomarker Results for GRI-0621 in Idiopathic Pulmonary Fibrosis Treatment - Nasdaq
GRI Bio, Inc. SEC 10-Q Report - TradingView
GRI Bio Reports First Quarter 2025 Financial Results and - GlobeNewswire
GRI Bio reports positive interim biomarker data in IPF study By Investing.com - Investing.com Nigeria
GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend - GlobeNewswire
GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect Of GRI-0621 - marketscreener.com
GRI Bio reports positive interim biomarker data in IPF study - Investing.com
GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - Yahoo Finance
GRI Bio Continues To Drive Enrollment In Ongoing Phase 2A Study Of GRI-0621 In Idiopathic Pulmonary Fibrosis - marketscreener.com
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewswire
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ('IPF”) - The Manila Times
GRI Bio (GRI) to Release Earnings on Friday - Defense World
GRI Bio Inc (GRI) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
FY2025 Earnings Forecast for GRI Bio Issued By HC Wainwright - Defense World
GRI Bio appoints Withum as new accounting firm By Investing.com - Investing.com Canada
GRI Bio Announces Abstract Selected for Poster Discussion - GlobeNewswire
Major Scientific Breakthrough: GRI Bio's Novel Pulmonary Fibrosis Treatment Shows Promise - Stock Titan
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):